| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/23/2006 | US20060040871 Bacterial transforming agent |
| 02/23/2006 | US20060040869 Pharmaceutically useful compounds |
| 02/23/2006 | US20060040851 Gag-peptide complex |
| 02/23/2006 | US20060040850 Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase IV activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differentiation states |
| 02/23/2006 | US20060040384 Serum free cultivation of primate embryonic stem cells |
| 02/23/2006 | US20060040371 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 02/23/2006 | US20060040360 Adipocyte complement related protein homolog zacrp7 |
| 02/23/2006 | US20060040331 Methods of screening apoptosis modulating compounds, compounds identified by said methods and use of said compounds as therapeutic agents |
| 02/23/2006 | US20060040307 A recombinant human telomerase reverse transcriptase (hTRT) protein; drug screening for antiproliferative agents that inhibit hTRT activity; cancer diagnosis and prognosis; anticarcinogenic agents |
| 02/23/2006 | US20060040266 Diagnostics and therapeutics for diseases associated with neuromedin u2 receptor (nmu2) |
| 02/23/2006 | US20060040259 Administering an inhibitor of prenyl cysteine methyltransferase; inhibiting the prenylation or a post-prenylation reaction of a protein contained in the virus infecting a subject |
| 02/23/2006 | US20060040254 Evaluate drugs capable of inhibiting the vanilloid receptor; establish a relaxed bronchial base line state; expose tissue to a dose of a contraction effective agent causing first tensioned state; expose tissue to the candidate substance; allow to return to a base line state |
| 02/23/2006 | US20060039998 Remedies |
| 02/23/2006 | US20060039995 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
| 02/23/2006 | US20060039992 Novel compositions and methods utilizing green-lipped mussel and fatty acids |
| 02/23/2006 | US20060039989 Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| 02/23/2006 | US20060039988 Azithromycin dosage forms with reduced side effects |
| 02/23/2006 | US20060039987 Method and apparatus for producing dry particles |
| 02/23/2006 | US20060039985 Methotrexate compositions |
| 02/23/2006 | US20060039979 Drug delivery system using subconjunctival depot |
| 02/23/2006 | US20060039978 Self-forming phospholipidic gels |
| 02/23/2006 | US20060039975 Paroxetine formulations |
| 02/23/2006 | US20060039974 Sustained release preparation |
| 02/23/2006 | US20060039973 Effervescent composition including water soluble dietary fiber |
| 02/23/2006 | US20060039970 Tamper-resistant oral opioid agonist formulations |
| 02/23/2006 | US20060039969 Gastrointestinal side effect reduction with lower mean Maximum concentrations (Cmax) than with an immediate release formulation, but equivalent bioavailability of clarithromycin and a water soluble alginate salt, a complex salt of alginic acid and an organic carboxylic acid |
| 02/23/2006 | US20060039968 Gabapentin tablets and method for their preparation |
| 02/23/2006 | US20060039967 Amino acid-containing chewable |
| 02/23/2006 | US20060039965 Drug delivery system for hydrophobic drugs |
| 02/23/2006 | US20060039962 Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting |
| 02/23/2006 | US20060039961 Percutaneous absorption accelerator |
| 02/23/2006 | US20060039960 Plaster containing fentanyl |
| 02/23/2006 | US20060039959 Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents |
| 02/23/2006 | US20060039954 Comprising two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate production of glutathione; macular degeneration |
| 02/23/2006 | US20060039953 Water soluble polymer such as pullulan and an antimicrobial effective amount of thymol, methyl salicylate, eucalyptol and/or menthol; killing the plaque-producing germs that cause dental plaque, gingivitis and bad breath |
| 02/23/2006 | US20060039950 Multi-functional biocompatible coatings for intravascular devices |
| 02/23/2006 | US20060039937 Composition having antioxidant properties |
| 02/23/2006 | US20060039935 Composition of a transdermal delivery system, which modulates inflammation, via insitu systems, thereby promoting repair of injured, damaged or diseased joints, and soft tissue. |
| 02/23/2006 | US20060039933 Method for treatment of insect bites |
| 02/23/2006 | US20060039932 Application of phytosteroids (and isomers thereof), folic acid, cyanocobalamine and pyridoxine in dietetic (alimentary) fibers |
| 02/23/2006 | US20060039931 Stable cream preparations of phenyl-pyridone compounds for topical application |
| 02/23/2006 | US20060039930 Methods for enhancing wound healing |
| 02/23/2006 | US20060039925 Mutants of streptococcal toxin a and methods of use |
| 02/23/2006 | US20060039921 Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus |
| 02/23/2006 | US20060039918 Stress proteins and peptides and methods of use thereof |
| 02/23/2006 | US20060039915 P-cadherin as a target for anti-cancer therapy |
| 02/23/2006 | US20060039914 Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| 02/23/2006 | US20060039898 Method of skin care and/or treatment using rice (Oryza sativa) hemoglobin or other hexacoordinated, non-symbiotic plant hemoglobins |
| 02/23/2006 | US20060039891 Antineoplastic-dendritic polymer drug delivery system |
| 02/23/2006 | US20060039890 Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant |
| 02/23/2006 | US20060039871 Beclomethasone powders has specific particle size distribution; increase bioavailability, prolonged therapeutic effect of the drug substance; aqueous suspension for inhalation; drug delivery method and device; rhinitis treatment |
| 02/23/2006 | US20060039869 Intranasal delivery of antipsychotic drugs |
| 02/23/2006 | US20060039868 For use in therapy of chronic obstructive pulmonary disease and asthma; an inhalette capsule contains a mixture of coarser and fine excipient particles |
| 02/23/2006 | US20060039867 Method for treating sleep-related breathing disorders with setiptiline |
| 02/23/2006 | US20060039866 Method for treating sleep-related breathing disorders |
| 02/23/2006 | US20060039862 Identification and use of growth hormone secretagogue receptor type 1A antagonists |
| 02/23/2006 | US20060039856 Magnetic resonance with stimulation |
| 02/23/2006 | US20060037910 Comprise liquid or dry acid concentrate unit stored in first vessel, and liquid or dry citrate-containing bicarbonate concentrate unit stored in second vessel; contents of first and second vessels are emptied into dialysate preparation tank and mixed with water to form batch of dialysate |
| 02/23/2006 | DE202005020404U1 Mixture for reduction of troubles or nourishment supplement in menopause, comprises phytoestrogen active agent, antioxidant and carrier agents |
| 02/23/2006 | DE20023745U1 Method of modulating expression of an endogenous cellular gene in a cell to prevent gene activation or prevent repression of gene expression comprising contacting a target sequence with a zinc finger protein |
| 02/23/2006 | DE10309929B4 Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung Benzoylureidopyridyl substituted-piperidine and -pyrrolidine carboxylic acid derivatives, processes for their preparation and their use |
| 02/23/2006 | DE102004040458A1 Vitreous humor tamponade product comprises solid particulate gas-generating reactants encapsulated in a biocompatible material with retarded solubility in aqueous media |
| 02/23/2006 | DE102004039382A1 Spirocyclische Cyclohexan-Derivate Spirocyclic cyclohexane derivatives |
| 02/23/2006 | DE102004039373A1 Para-Alkyl-substituierte N-(4-Hydroxy-3-methoxy-benzyl)-zimtsäureamide und deren Verwendung zur Herstellung von Arzneimitteln Para-alkyl-substituted N- (4-hydroxy-3-methoxy-benzyl) -cinnamic acid amides and their use for the preparation of medicaments |
| 02/23/2006 | DE102004039280A1 1,5-Diphenyl-pyrazole 1,5-diphenyl-pyrazoles |
| 02/23/2006 | DE102004039096A1 New D-xylopyranosyl-phenyl-substituted cycle compounds useful for treating e.g. diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis |
| 02/23/2006 | DE102004039065A1 New N-substituted 1-benzyl-1H-(1,2,3)-triazole-4-carboxamides, are dopamine and alpha-1 adrenergic receptor ligands useful for treating diseases of the urinary tract, vascular system or CNS |
| 02/23/2006 | DE102004038885A1 Aerosolformulierung für die Inhalation enthaltend ein Anticholinergikum Aerosol formulation for inhalation containing an anticholinergic |
| 02/23/2006 | DE102004038535A1 Zelluläre Einschleusung von Nukleinsäurewirkstoffen Cellular introduction of nucleic acid drugs |
| 02/23/2006 | DE102004037911A1 New mixed cage dimers of 4-phenyl-1,4-dihydropyridine derivatives, useful as HIV-1 protease inhibiting anti-HIV agents which also modulate HIV resistance by inhibiting P-glycoprotein |
| 02/23/2006 | DE102004037885A1 New cage dimers of 4-phenyl-1,4-dihydropyridine derivatives, useful as HIV-1 protease inhibiting anti-HIV agents and for increasing resorption and bioavailability of other anti-HIV drugs |
| 02/23/2006 | DE102004037505A1 Präbiotische Intimpflege Prebiotic intimate care |
| 02/23/2006 | DE102004034619A1 Substituierte Aminoverbindungen als 5-HT/NA Uptakehemmer Substituted amino compounds as 5-HT / NA Uptakehemmer |
| 02/23/2006 | CA2781626A1 Use of xenon as neuroprotectant in a neonatal subject |
| 02/23/2006 | CA2777473A1 Compounds and methods for the treatment of cancer |
| 02/23/2006 | CA2619779A1 Use of a pde5 inhibitor for treating and preventing hypopigmentary disorders |
| 02/23/2006 | CA2618985A1 Pharmaceutical composition and method for treating neurodegenerative disorders |
| 02/23/2006 | CA2589971A1 Method of treating trauma or sepsis |
| 02/23/2006 | CA2581327A1 Intracellular receptor modulator compounds and methods |
| 02/23/2006 | CA2579764A1 Methods of regulating differentiation and treating of multiple myeloma |
| 02/23/2006 | CA2579449A1 Galenic applications of self-emulsifying mixtures of lipidic excipients |
| 02/23/2006 | CA2578636A1 Thienopyridines for treating hepatitis c |
| 02/23/2006 | CA2578529A1 Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists |
| 02/23/2006 | CA2578280A1 Arene ruthenium (ii) compounds and their use in cancer therapy |
| 02/23/2006 | CA2578098A1 Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl) benzamide, methods for the production thereof, and use thereof as medicaments |
| 02/23/2006 | CA2577880A1 Compounds useful for inhibiting chk1 |
| 02/23/2006 | CA2577698A1 Infant formula |
| 02/23/2006 | CA2577668A1 Novel antidiabetic compounds |
| 02/23/2006 | CA2577648A1 Triazolopyridine compounds useful for the treatment of inflammation |
| 02/23/2006 | CA2577478A1 Triazolopyridine compounds |
| 02/23/2006 | CA2577448A1 Androgen modulators |
| 02/23/2006 | CA2577429A1 Amphiphilic polynorbornene derivatives and methods of using the same |
| 02/23/2006 | CA2577345A1 Jelly composition |
| 02/23/2006 | CA2577274A1 Anti-inflammatory agents |
| 02/23/2006 | CA2577261A1 Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament |
| 02/23/2006 | CA2577255A1 Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament |
| 02/23/2006 | CA2577213A1 Use of gsk-3 inhibitors for the treatment of prostate cancer |
| 02/23/2006 | CA2577169A1 Metabolism-modulating agents and uses therefor |
| 02/23/2006 | CA2577135A1 Deuterium depleted water (ddw) using as adjuvant in cancer therapy for cytostatics toxicity reduction |
| 02/23/2006 | CA2577036A1 Small interfering rna molecules against ribonucleotide reductase and uses thereof |